Entrada Therapeutics Statistics
Total Valuation
TRDA has a market cap or net worth of $260.35 million. The enterprise value is -$14.08 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TRDA has 35.86 million shares outstanding. The number of shares has increased by 15.95% in one year.
| Current Share Class | 35.86M |
| Shares Outstanding | 35.86M |
| Shares Change (YoY) | +15.95% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 49.98% |
| Float | 19.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.86 |
| Forward PS | 7.18 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.08, with a Debt / Equity ratio of 0.15.
| Current Ratio | 14.08 |
| Quick Ratio | 13.74 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.11% and return on invested capital (ROIC) is -17.33%.
| Return on Equity (ROE) | -27.11% |
| Return on Assets (ROA) | -15.71% |
| Return on Invested Capital (ROIC) | -17.33% |
| Return on Capital Employed (ROCE) | -31.26% |
| Revenue Per Employee | $336,175 |
| Profits Per Employee | -$565,328 |
| Employee Count | 183 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.04M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.37% in the last 52 weeks. The beta is -0.09, so TRDA's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | -63.37% |
| 50-Day Moving Average | 6.00 |
| 200-Day Moving Average | 7.96 |
| Relative Strength Index (RSI) | 63.83 |
| Average Volume (20 Days) | 213,223 |
Short Selling Information
The latest short interest is 944,223, so 2.63% of the outstanding shares have been sold short.
| Short Interest | 944,223 |
| Short Previous Month | 813,393 |
| Short % of Shares Out | 2.63% |
| Short % of Float | 4.87% |
| Short Ratio (days to cover) | 2.86 |
Income Statement
In the last 12 months, TRDA had revenue of $61.52 million and -$103.46 million in losses. Loss per share was -$2.52.
| Revenue | 61.52M |
| Gross Profit | -80.20M |
| Operating Income | -121.56M |
| Pretax Income | -104.49M |
| Net Income | -103.46M |
| EBITDA | -117.36M |
| EBIT | -121.56M |
| Loss Per Share | -$2.52 |
Full Income StatementBalance Sheet
The company has $326.84 million in cash and $52.40 million in debt, giving a net cash position of $274.44 million or $7.65 per share.
| Cash & Cash Equivalents | 326.84M |
| Total Debt | 52.40M |
| Net Cash | 274.44M |
| Net Cash Per Share | $7.65 |
| Equity (Book Value) | 340.72M |
| Book Value Per Share | 9.50 |
| Working Capital | 314.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$127.91 million and capital expenditures -$1.88 million, giving a free cash flow of -$129.80 million.
| Operating Cash Flow | -127.91M |
| Capital Expenditures | -1.88M |
| Free Cash Flow | -129.80M |
| FCF Per Share | -$3.62 |
Full Cash Flow StatementMargins
Gross margin is -130.36%, with operating and profit margins of -197.59% and -168.16%.
| Gross Margin | -130.36% |
| Operating Margin | -197.59% |
| Pretax Margin | -169.85% |
| Profit Margin | -168.16% |
| EBITDA Margin | -190.76% |
| EBIT Margin | -197.59% |
| FCF Margin | n/a |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.95% |
| Shareholder Yield | -15.95% |
| Earnings Yield | -39.74% |
| FCF Yield | -49.85% |
Analyst Forecast
The average price target for TRDA is $24.50, which is 237.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.50 |
| Price Target Difference | 237.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TRDA has an Altman Z-Score of 2.57 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.57 |
| Piotroski F-Score | 1 |
